A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints (Q38015026)

27 August 2017

title

A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints (English)

1 reference

27 August 2017

1 reference

Philippe L Bedard

2

0 references

Sherene Loi

object named as

Sherene Loi

6

0 references

Stefan Michiels

object named as

Stefan Michiels

4

0 references

author name string

Debora Fumagalli

1

1 reference

27 August 2017

Zeina Nahleh

3

1 reference

27 August 2017

Christos Sotiriou

5

1 reference

27 August 2017

Joseph A Sparano

7

1 reference

27 August 2017

Matthew Ellis

8

1 reference

27 August 2017

Nola Hylton

9

1 reference

27 August 2017

Jo Anne Zujewski

10

1 reference

27 August 2017

Clifford Hudis

11

1 reference

27 August 2017

Laura Esserman

12

1 reference

27 August 2017

Martine Piccart

13

1 reference

27 August 2017

BIG-NABCG collaboration

14

1 reference

27 August 2017

publication date

1 June 2012

1 reference

Lancet Oncology Commission

27 August 2017

published in

1 reference

27 August 2017

volume

13

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

e240-8

1 reference

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Histological types of breast cancer: how special are they?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Preoperative systemic chemotherapy and pathologic assessment of response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Molecular imaging of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Triple-negative breast cancer: are the imaging findings different between responders and nonresponders to neoadjuvant chemotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Accuracy of MRI in the Detection of Residual Breast Cancer After Neoadjuvant Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: relation to response patterns on MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

The role of PET CT to evaluate the response to neoadjuvant chemotherapy in advanced breast cancer: comparison with ultrasonography and magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography of breast cancer in detecting axillary lymph node metastasis: comparison with ultrasonography and contrast-enhanced CT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Monitoring therapeutic efficacy in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Supervised risk predictor of breast cancer based on intrinsic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Breast cancer molecular profiling with single sample predictors: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Gene-expression signatures in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Genomic grade index is associated with response to chemotherapy in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970378-3

7 January 2021

10.1016/S1470-2045(11)70378-3

Identifiers

DOI

1 reference

27 August 2017

1 reference